Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (727)	4/23/1999 4:21:00 PM
From: LLCF	Read Replies (3) \| Respond to of 2001

I think I'll toss $36 mill into the sales & revenue number on the value spreadsheet... GLIA is working it's way to the top of the value spreadsheet in burn terms. Cash increased by a million as well. DAK

To: scaram(o)uche who wrote (727)	4/23/1999 7:14:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 2001

Perceptin, huh? Sounds too much like herceptin -- they should probably shoot for something else. Besides, 4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]-1H-imidazole has a much nicer ring to it. Seriously, I hope they do start the PIIa trials. Partnering a drug with demonstrated clinical efficacy is much more profitable. It's a risk, but one I hope they take.